1 Mørk SK, et al. J Immunother Cancer 2024;12:e008817. doi:10.1136/jitc-2024-008817Open access Dose escalation study of a personalized peptide- based neoantigen vaccine (EVX- 01) in patients with metastatic melanoma Sofie Kirial Mørk ,1 Signe Koggersbøl Skadborg,2 Benedetta Albieri,1 Arianna Draghi ,1 Kalijn Bol ,3 Mohammad Kadivar,2 Marie Christine Wulff Westergaard,1 Joachim Stoltenborg Granhøj,1 Annie Borch,2 Nadia Viborg Petersen,4 Nikolas Thuesen,4 Ida Svahn Rasmussen,5 Lars Vibe Andreasen,5 Rebecca Bach Dohn,5 Christina Westmose Yde,6 Nis Noergaard,7 Torben Lorentzen,8 Anders Bundgaard Soerensen,4 Daniela Kleine- Kohlbrecher,4 Anders Jespersen,4 Dennis Christensen,5 Jens Kringelum,4 Marco Donia ,1 Sine Reker Hadrup ,2 Inge Marie Svane1 To cite: Mørk SK, Skadborg SK, Albieri B, et al. Dose escalation study of a personalized peptide- based neoantigen vaccine (EVX- 01) in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer 2024;12:e008817. doi:10.1136/ jitc-2024-008817 ►Additional supplemental material is published online only. To view, please visit the journal online (https:// doi. org/ 10.